

Louisiana Department of Health Informational Bulletin 16-9

Revised January 6, 2023

340B Policy Clarification

1 SUMMARY

- The overlap of the 340B Drug Pricing Program and the Medicaid Drug Rebate program creates the possibility of duplicate discounts, which are prohibited under federal law.
- States are federally mandated to seek federal drug rebates on managed care Medicaid claims, meaning that the potential for duplicate discounts exists for managed care claims.
- Louisiana uses the Health Resources and Services Administration's (HRSA) Medicaid Exclusion File (MEF) for both Fee-for-Service (FFS) and managed care Medicaid claims in order to prevent duplicate discounts.
- **Contract pharmacies** are not permitted to bill Medicaid for drugs purchased at 340B pricing. This includes **both** FFS and managed care Medicaid.
- Effective July 15, 2019, pharmacy claims submitted by pharmacies on the MEF for hepatitis C virus direct-acting antiviral (DAA) agents will deny.
- Starting June 1, 2020, all 340B pharmacy claims shall deny when the appropriate 340B claim level indicators are not included.

2 340B & DRUG REBATE PROGRAM BACKGROUND

The national Medicaid Drug Rebate program was established in 1991 as a means to offset both state and federal Medicaid drug expenditures. When a drug manufacturer enters into a national rebate agreement, they are also required to enter into an agreement with the 340B Drug Pricing Program.

The 340B Drug Pricing Program was designed to enable participating providers, referred to as "covered entities," to stretch scarce federal resources by obtaining covered outpatient drugs at significantly discounted prices. This program is administered by HRSA's Office of Pharmacy Affairs (OPA).

When a covered entity bills Medicaid for a pharmacy or outpatient physician-administered drug, the possibility of duplicate discounts exists due to the overlap of the Medicaid Drug Rebate and 340B Drug Pricing Programs. Therefore, when a covered entity enrolls in the 340B program, it must choose whether it will "carve-in" or "carve-out" its **Medicaid** patients. Carve-in means that drugs purchased

under the 340B Drug Pricing Program will be billed to Medicaid. Carve-out means that **no** drugs purchased under the 340B Drug Pricing Program will be billed to Medicaid.

Additional information on the 340B Drug Pricing Program can be found at http://www.hrsa.gov/opa.

3 MEDICAID EXCLUSION FILE

HRSA communicates carve-in designations to states via the Medicaid Exclusion File (MEF) in order to alert states that Medicaid Drug Rebates should not be sought on MEF providers' drug claims.

When a covered entity chooses to carve-in, it must provide HRSA with the National Provider Identification (NPI) and Medicaid provider number for each site that carves in for the purpose of inclusion in the MEF. An entry in the MEF indicates that a covered entity has chosen to carve-in for a single quarter. Louisiana carve-in 340B covered entities shall be fully enrolled in Louisiana Medicaid and must provide HRSA with the seven-digit Louisiana Medicaid Provider number.

A covered entity can change its carve-in or carve-out designation; however, HRSA stipulates that the effective date of any such change will be the first day of a calendar quarter. Status changes for the next calendar quarter must be provided by the 15th day of the month preceding the quarter's start (March 15, June 15, Sep. 15 and Dec. 15). Changes submitted after this date will not be effective until the start of the second quarter following the change. Because the MEF is produced on the 15th day of the month preceding a quarter's start, this ensures that an entity's carve-in or carve-out election is properly reflected on the applicable quarter's MEF.

States can elect to identify 340B claims using methods other than the exclusion file (e.g. claim-level indicators). Louisiana currently uses the MEF to identify 340B drug claims. Louisiana also requires the claim level indicators to be present on all submitted 340B pharmacy claims.

Additional information regarding the MEF can be found at: https://www.hrsa.gov/opa/updates/2015-october.

4 MANAGED CARE MEDICAID

Section 2501(c) of the Patient Protection and Affordable Care Act (ACA) requires state Medicaid agencies to seek rebates on drugs dispensed by Medicaid managed care organizations (MCO). This means that the potential for duplicate discounts exists for both FFS and managed care Medicaid.

Due to this duplicate discount potential, Louisiana requires that covered entities utilize the same carve-in or carve-out designation for managed care Medicaid patients as for FFS Medicaid patients. If a covered entity appears on the MEF, Louisiana will exclude that provider's FFS and MCO claims from rebate invoicing. Since claims for FFS Medicaid and managed care Medicaid recipients are treated identically in regard to exclusion from rebate invoicing, any reference to "Medicaid recipients" in this document refers to both FFS and managed care Medicaid recipients.

In order to allow covered entities to identify managed care Medicaid patients from an MCO's private insurance patients, Louisiana requires its MCOs to utilize a unique Processor Control Number (PCN) or group number for Louisiana Medicaid.

Louisiana Medicaid FFS and MCO BIN, PCN, and group numbers for pharmacy claims:

Plan Name	PBM Name	BIN	PCN	Group
Aetna	CVS Health	610591	ADV	RX8834
AmeriHealth Caritas	PerformRx	019595	06030000	n/a
Healthy Blue	CVS	020107	FG	WKLA
Humana Healthy Horizons*	<u>Gainwell</u>	<u>610514</u>	LOUIPROD	<u>HUMANA</u>
	<u>Technologies</u>			
Louisiana Healthcare	CVS Caremark	004336	MCAIDADV	RX5444
Connections				
United Healthcare	OptumRx	610494	9999	ACULA
Fee-for-Service	DXC Gainwell	610514	LOUIPROD	n/a
	<u>Technologies</u>			

^{*}Humana will become a Louisiana Medicaid MCO effective January 1, 2023.

Payer ID can be utilized to identify managed care Medicaid recipients' medical claims. Please refer to the <u>Provider & Plan Resources page</u> for information regarding Electronic Data Interchange (EDI) claim submissions.

5 CONTRACT PHARMACIES

HRSA permits covered entities to contract with one or more pharmacies to provide services to the covered entity's patients in order to increase patient access to 340B drugs.

HRSA expressly prohibits contract pharmacies from dispensing drugs purchased under the 340B Drug Pricing Program to Medicaid recipients unless the covered entity, the contract pharmacy, and the state Medicaid agency have established an arrangement to prevent duplicate discounts (75 FR 10272, March 5, 2010)¹. Louisiana currently has no such agreements in place and requires that all contract pharmacies carve out Medicaid recipients for both FFS and MCO 340B drug claims.

Effective Sept. 12, 2017, pharmacy claims shall deny at Point of Sale (POS) if 340B indicators are on the claim but the pharmacy is not listed in the MEF. These claims shall be filled with regular pharmacy stock, not 340B stock, and billed accordingly.

6 CURRENT BILLING GUIDELINES

For full billing procedures, please refer to each MCO's provider manual.

6.1 Carve-In

6.1.1 Claim-level Indicators

¹Full text from Federal Register (FR) available at <u>www.federalregister.gov</u>

Beginning with date of service Sept. 12, 2017, providers shall submit both FFS and managed care claims with the claim-level indicators below.

Effective June 1, 2020, 340B pharmacy claims will deny at POS if the following claim-level indicators are not present.

6.1.1.1 Pharmacy Claims

340B Pharmacy claims shall contain BOTH indicators below:

NCPDP Field	NCPDP Field Name	NCPDP Values
420-DK	Submission Clarification	20 = 340B
	Code	
423-DN	Basis of Cost	08 = 340B
	Determination	Disproportionate Share
		Pricing

6.1.1.2 Physician-Administered Drug Claims

Providers shall submit the UD modifier to identify 340B drugs on outpatient physician-administered drug claims. This includes outpatient professional service 340B drug claims. Due to the cost-to-charge methodology, outpatient hospital claims are excluded from the claim-level indicator requirement.

- CMS 1450/UB04: Enter UD Modifier immediately following drug HCPCS/CPT code in field 44. For example, HCPCS J1111 billed as J1111UD.
- CMS 1500: Enter HCPCS code in field 24C followed by the UD Modifier.
- **837I**: Loop 2400 SV2 can send up to four modifiers SV202-3, SV202-4, SV202-5, and SV202-6.
- 837P: Loop 2400 SV1 can send up to four modifiers in SV101-3, SV101-4, SV101-5, and SV101-6.

6.1.2 FFS Pharmacy

Covered entities who carve in Medicaid recipients should bill a drug's actual acquisition cost in National Council for Prescription Drug Programs (NCPDP) field 409-D9 Ingredient Cost Submitted.

6.1.3 MCO Pharmacy

Covered entities who carve-in Medicaid recipients should bill according to the contract arrangements between the 340B covered entity and the MCO.

Contract pharmacies are not permitted to carve-in FFS or MCO Medicaid for drugs purchased at 340B prices.

6.1.4 Hepatitis C Virus Direct-Acting Antiviral (DAA) Agents

Starting July 15, 2019, the Louisiana Hepatitis C Elimination Program was implemented to address the public health crisis caused by hepatitis C. The Louisiana Department of Health and the Department of Corrections have entered into a five-year contract with

Asegua Therapeutics, a wholly owned subsidiary of Gilead Sciences, Inc., to provide unrestricted access to its authorized generic of Epclusa (sofosbuvir/velpatisvir) for treatment of hepatitis C among Medicaid recipients and incarcerated patients.

For Medicaid recipients, a supplemental rebate agreement was utilized. Therefore, as 340B Medicaid claims cannot be included in supplemental rebate agreements, claims for hepatitis C direct-acting antiviral agents from 340B pharmacies carved-in to Medicaid will deny at POS.

Claims for hepatitis C direct-acting antiviral agents from 340B carve-out pharmacies are not subject to this limitation and will process as usual.

6.1.5 Vaccines for Adults

Effective July 1, 2020, 340B pharmacies carved in to Medicaid may bill vaccines and administration for adults (19 years and older) at POS as a pharmacy benefit. Claim-level indicators should not be included on claims for vaccines, as vaccines are not 340B or rebate-eligible.

6.2 Carve-Out and Contract Pharmacies

Covered entities who carve out Medicaid recipients and contract pharmacies shall bill according to guidelines provided in each MCO's provider manual for non-340B drug claims. Links have been provided below:

Aetna	http://www.aetnabetterhealth.com/louisiana/providers/manual
AmeriHealth Caritas	https://www.performrx.com/who-we-help/providers/provider-resources.aspx
Healthy Blue	https://providers.healthybluela.com/la/pages/manuals-directories-more.aspx
Humana Healthy Horizons	https://www.lamedicaid.com/Provweb1/Providermanuals/manuals/PHARMACY/PHARMACY.pdf
Louisiana Healthcare Connections	http://www.louisianahealthconnect.com/for-providers/provider-resources/
United Healthcare	http://www.uhccommunityplan.com/health-professionals/la.html
Fee-for- Service	https://www.lamedicaid.com/Provweb1/Providermanuals/manuals/PHARMACY/PHARMACY.pdf http://www.lamedicaid.com/provweb1/Providermanuals/Intro_Page.aspx

7 REIMBURSEMENT

7.1 Fee-for-Service

As of May 1, 2017, FFS Pharmacy Outpatient claims for drugs purchased at 340B rates will be reimbursed at Actual Acquisition Cost plus a professional dispensing fee or Usual and Customary, whichever is less.

Reimbursement methodologies for physician-administered drugs not billed as a pharmacy claim will not change.

Outpatient hospital claims for physician-administered drugs will continue to be paid using a cost-to-charge methodology on the interim and are settled at cost during final settlement. FQHC and RHC claims for physician-administered drugs will be included in the all-inclusive T1015 encounter rate as they are currently.

Providers can also contact the appropriate department listed below for further information:

FFS Program	Reimbursement Questions Contact	Phone
Pharmacy	Pharmacy Help Desk	800-437-9101
All Others	DXC Gainwell Technology Provider	800-473-2783
(Hospital, Professional	Relations	
Services, etc.)		

7.2 Managed Care

Managed care reimbursements are made in accordance with contractual arrangements between the covered entity and MCO.

For questions about reimbursement, please contact the provider relations department of the appropriate MCO.

Name	Provider
	Relations
Aetna	855-242-0802
AmeriHealth Caritas	888-922-0007
Healthy Blue	844-521-6942
<u>Humana</u>	800-448-3810
Louisiana Healthcare Connections	866-595-8133
United Healthcare	866-675-1607

8 POLICY COMPLIANCE

Noncompliance with this policy may result in recoupments, sanctions, and/or other disciplinary action taken against the provider.

9 QUESTIONS

If you have questions about the contents of this memo, you may contact:

Contact Name	Email	Phone
Sharon Beckwith	Sharon.Beckwith@la.gov	225-342-9859

Jennie Stelly <u>Jennie.Stelly@la.gov</u> 225-342-4665

Medicaid Pharmacy

Medicaid.Pharmacy@la.gov

800-437-9101

Help Desk

Healthy Louisiana Informational Bulletin 16-9 Attachment: EDI Submission Information for Healthy Louisiana Plans

Rev 01/2023

Managed Care Organizations Electronic Data Interchange Submissions

Aetna Better Health of Louisiana Payer ID 128LA

Emdeon www.emdeon.com 877-469-3263

Emdeon is the EDI vendor we use. Providers need to **contact** the software vendor directly for further questions about their electronic billing. All electronic submissions shall be submitted in compliance with applicable law including HIPAA regulations and Aetna Better Health of Louisiana policies and procedures. If you use a clearinghouse other than Emdeon, please have them call Emdeon at the following number in order to establish connectivity: 800-845-6592. (Please run a test claim prior to submitting batches.) Please use the Payer ID above when submitting claims to Aetna Better Health of Louisiana. For pharmacy resources, visit https://www.caremark.com/wps/portal and click on Pharmacists & Medical Professionals.

AmeriHealth Caritas Payer ID 27357

Trading Partner: Change Healthcare

For ACLA EDI questions: Email – edi@amerihealthcaritasla.com ACLA EDI Phone – 866-428-7419 Change Healthcare Phone – 877-363-3666

Healthy Blue

Trading Partners:

Availity - Claim Payer ID 00661

Change Healthcare (formerly Capario, Emdeon, MedAvant or WebMD) – Claim Payer ID 58532 Smart Data Solutions – Claim Payer ID 16730 or 58532

A provider who wishes to submit directly to Healthy Blue should contact Availity ACS at 800-282-4548 or navigate to <u>Availity.com</u> to start the electronic claims submission process, or with any questions.

Humana

Trading Partners:

The following are some of the many clearinghouses offering services to healthcare providers. Some clearinghouses and vendors charge a service fee. Contact the clearinghouse for more information:

Clearinghouse Vendor Name	<u>Website</u>	Phone Number
Availity	<u>Availity.com</u>	800-282-4548
<u>McKesson</u>	McKesson.com	N/A
WayStar	Waystar.com	<u>877-494-7633</u>
<u>Trizetto</u>	<u>Trizetto.com</u>	<u>800-969-3666</u>
Change Healthcare (formerly	<u>Changehealthcare.com</u>	<u>800-792-5256</u>
Emdeon)		
SSI Group	<u>TheSSIGroup.com</u>	800-880-3032

When filing an electronic claims, use one of the following:

- 61101 for fee-for-service claims
- 61102 for encounter claims

Humana claim payment inquiries: 800-448-3810, Monday through Friday, 8 a.m. to 6 p.m.

Louisiana Healthcare Connections Payer ID 68069

Trading Partners:

Emdeon/Change Healthcare MedAvant/Capario/Emdeon Availity
Gateway EDI/TriZetto Smart Data Solutions Infinedi
Experian Encoda ClaimRemedi

Allscripts/PayerPath ViaTrack GHN-Online/Greenway Eligibility

MD On-line/Ability Relay Health/McKesson Practice Insight SSI ZirMed InMediata

For support: 800-225-2573 Ext. 6075525 or via email at EDIBA@centene.com.

UnitedHealthcare Payer ID 87726

For EDI questions or list of clearinghouses:

Phone - 800-842-1109 or 800-210-8315

Email – ac edi ops@uhc.com

Current Trading Partners include (but not limited to):

Allscripts Availity Capario
Emdeon Gateway EDI/TriZetto MD Online
MedAssets Navicure Office Ally
OptumInsight Practice Insight RealMed
RelayHealth SSI ZirMed